Compare VHC & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | ATYR |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 69.2M |
| IPO Year | 1999 | 2015 |
| Metric | VHC | ATYR |
|---|---|---|
| Price | $20.41 | $0.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 32.5K | ★ 1.5M |
| Earning Date | 03-16-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $106,000.00 | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2020.00 | N/A |
| 52 Week Low | $6.60 | $0.64 |
| 52 Week High | $29.00 | $7.29 |
| Indicator | VHC | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 38.65 |
| Support Level | $19.27 | $0.69 |
| Resistance Level | $22.67 | $0.76 |
| Average True Range (ATR) | 1.56 | 0.04 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 40.62 | 14.40 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.